PDT of NCP@pyrolipid in combination with anti-PD-L1 treatment presents three regimens—oxaliplatin, PDT and checkpoint blockade therapy—to elicit synergistic effects in enhancing antitumour immunity for the effective treatment of metastatic colorectal cancer. This evidence concerns the gene CD274 and metastatic colorectal cancer.